![3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one structure](/static/products/7273/727392-92-9.webp)
3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one
TL;DR: 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one (CAS 727392-92-9) is a chemical compound with molecular formula C24H23N3O and molecular weight 369.18 g/mol, supplied by Kehong Biological (Henan Kehong Biological Technology Co., Ltd.) with CRO/CDMO custom synthesis services.
3-phenylspiro[2,3,4,5-tetrahydrobenzimidazolo[2,1-b]quinazoline-12,1'-cyclopentane]-1-one
Also Known As: 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one, 3-phenylspiro[2,3,4,5-tetrahydrobenzimidazolo[2,1-b]quinazoline-12,1'-cyclopentane]-1-one, 3-phenylspiro[2,3,4,5,11,12-hexahydrobenzimidazolo[2,1-b]quinazoline-12,1'-cyc lopentane]-1-one
| Molecular Formula | C24H23N3O |
|---|---|
| Molecular Weight | 369.18 g/mol |
| LogP | 5.1319 |
| Topological Polar Surface Area | 46.92 Ų |
| Hydrogen Bond Donors | 1 |
| Hydrogen Bond Acceptors | 3 |
| Rotatable Bonds | 1 |
| Exact Mass | 369.1841 |
| Heavy Atoms | 28 |
| Complexity | 1119.2177 |
Chemical Identifiers
| CAS Number | 727392-92-9 |
|---|---|
| SMILES | C1CCC2(C1)C3=C(CC(CC3=O)C4=CC=CC=C4)NC5=NC6=CC=CC=C6N25 |
Product Overview
3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one (CAS 727392-92-9), with molecular formula C24H23N3O and molecular weight 369.18 g/mol. IUPAC: 3-phenylspiro[2,3,4,5-tetrahydrobenzimidazolo[2,1-b]quinazoline-12,1'-cyclopentane]-1-one.
Chemical Property Profile of 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one
Property Insights of 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one
The XLogP value of 5.1319 indicates that 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one is lipophilic (fat-soluble), which may influence its absorption, distribution, and formulation strategy. With a topological polar surface area (TPSA) of 46.92 Ų, 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one exhibits relatively low polarity, potentially indicating favorable cell membrane permeability. Following Lipinski's Rule of Five, 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one has 1 hydrogen bond donor(s) and 3 hydrogen bond acceptor(s), which may warrant consideration for formulation optimization.
Frequently Asked Questions
Frequently Asked Questions
What is the CAS number of 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one?
The CAS number of 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one is 727392-92-9.
What is the molecular formula of 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one?
The molecular formula of 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one is C24H23N3O.
What is the molecular weight of 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one?
The molecular weight of 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one is 369.18 g/mol.
Where can I buy 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one?
You can request a quote for 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one directly from KEHONG BIO. Contact us or email info@kehongbio.com for pricing and availability.
Does KEHONG BIO offer custom synthesis for 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one?
Yes, KEHONG BIO provides custom synthesis services for 3-phenyl-3,4-dihydro-2H-spiro[benzimidazo[2,1-b]quinazoline-12,1'-cyclopentan]-1(5H)-one and related compounds. Contact us with your specific requirements including quantity, purity, and timeline.